胃不全麻痺治療薬の世界市場...市場調査レポートについてご紹介

【英文タイトル】Global Gastroparesis Drugs Market 2017-2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: Disease overview

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by disease type
• Diabetic gastroparesis
• Idiopathic gastroparesis
• Others

PART 09: Market segmentation by drug class
• Prokinetic agents
• Antiemetic agents
• Botulinum toxin injection

PART 10: Geographical segmentation
• Gastroparesis drugs market in Americas
• Gastroparesis drugs market in EMEA
• Gastroparesis drugs market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges
• Market drivers
• Market challenges

PART 13: Market trends
• Fast track approvals and acquisitions to change the phase of the market
• Introduction of novel ways for the treatment of gastroparesis symptoms

PART 14: Vendor landscape
• Competitive scenario
• Cadila Pharmaceuticals
• GlaxoSmithKline
• Johnson & Johnson
• Valeant
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]

Exhibit 01: Causes of gastroparesis
Exhibit 02: Major complications associated with gastroparesis
Exhibit 03: Diagnosis and treatment of gastroparesis
Exhibit 04: Global gastroparesis drugs market snapshot
Exhibit 05: Global gastroparesis drug market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global gastroparesis drugs market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline summary based on vendors
Exhibit 09: Key clinical trials
Exhibit 10: Segmentation of global gastroparesis drugs market by disease type 2016
Exhibit 11: Global gastroparesis drugs market share by disease type 2016 (%)
Exhibit 12: Market snapshot: Global gastroparesis drugs market 2016-2021
Exhibit 13: Function of vagus nerves in digestive system
Exhibit 14: Global diabetic gastroparesis drugs market 2016-2021 ($ millions)
Exhibit 15: Global idiopathic gastroparesis drugs market 2016-2021 ($ millions)
Exhibit 16: Other causes of gastroparesis
Exhibit 17: Global gastroparesis drugs market by other causes 2016-2021 ($ millions)
Exhibit 18: Segmentation of global gastroparesis drug market by drug class
Exhibit 19: Market analysis of gastroparesis drug class
Exhibit 20: Global gastroparesis drugs market based on geography 2016 and 2021
Exhibit 21: Global gastroparesis drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 22: Market scenario in Americas
Exhibit 23: Gastroparesis drugs market in the Americas 2016-2021 ($ millions)
Exhibit 24: Top American countries with diabetic population range (millions)
Exhibit 25: Market scenario in EMEA
Exhibit 26: Gastroparesis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 27: Market scenario in APAC
Exhibit 28: Top Asian countries with diabetic population range (millions)
Exhibit 29: Gastroparesis drugs market in APAC 2016-2021 ($ millions)
Exhibit 30: New cases of diabetes by 2040
Exhibit 31: Possible treatments for gastroparesis.
Exhibit 32: Alternate treatment options for gastroparesis
Exhibit 33: Factors affecting the diagnosis of gastroparesis
Exhibit 34: Strategic success factors of companies in global gastroparesis drug market
Exhibit 35: Competitive structure analysis of global gastroparesis market
Exhibit 36: Cadila Pharmaceuticals: Key highlights
Exhibit 37: Cadila Pharmaceuticals: Strength assessment
Exhibit 38: Cadila Pharmaceuticals: Strategy assessment
Exhibit 39: Cadila Pharmaceuticals: Opportunity assessment
Exhibit 40: GlaxoSmithKline: Key highlights
Exhibit 41: GlaxoSmithKline: Strength assessment
Exhibit 42: GlaxoSmithKline: Strategy assessment
Exhibit 43: GlaxoSmithKline: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Valeant: Key highlights
Exhibit 49: Valeant: Strength assessment
Exhibit 50: Valeant: Strategy assessment
Exhibit 51: Valeant: Opportunity assessment


【レポート販売概要】

■ タイトル:胃不全麻痺治療薬の世界市場
■ 英文:Global Gastroparesis Drugs Market 2017-2021
■ 発行日:2017年5月3日
■ 調査会社:Technavio
■ 商品コード:IRTNTR13089
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。